Prilenia Therapeutics News and Activities

View the org chart displaying its 27 main executives

Most searched biographies at Prilenia Therapeutics

• Michael Hayden, Chief Executive Officer and Director
• Stefan Larson, Director
• Stephen Zachary, Director

Popular executive movements at Prilenia Therapeutics

• Elisabeth Leiderman has joined the company as Chief Financial Officer  (posted on April 29 2026).
• Andres Cruz-Herranz, Director of Clinical Development, has left the company  (posted on April 29 2026).
• Rob Lauzen, Chief Financial Officer, has left the company  (posted on November 4 2025).

Create your alert
to follow the executive moves at Prilenia Therapeutics.

Prilenia Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Prilenia Therapeutics

• Prilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease Research
• Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer
• Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS
• Muscular Dystrophy Association Clinical & Scientific Congress | Prilenia Therapeutics B.V.
• Shareable Online Calendar and Scheduling - Google Calendar
• Longwood Healthcare Leaders San Francisco CEO | Prilenia Therapeutics B.V.
• Shareable Online Calendar and Scheduling - Google Calendar
• Prilenia and Ferrer Announce FDA Clearance to Start the “PREVAiLS” Pivotal Phase 3 Study with Pridopidine in ALS
• HSG 2025 HD Clinical Research Congress | Prilenia Therapeutics B.V.
• Prilenia and Ferrer to Share New Data and Analyses of Pridopidine’s Impact on Huntington’s Disease at the Huntington Study Group (HSG) Congress
• View more press releases Close

Social media about Prilenia Therapeutics

• Prilenia Therapeutics on Wikipedia, Google News & Yahoo Finance
• Prilenia Therapeutics on LinkedIn, X (Twitter) & YouTube